CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 199 enrolled
Drug / intervention
Nab-Paclitaxel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02033993
NCT02033993Phase 2Completed
CompareCT.gov

A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advanced Urothelial Cancer Progressing on or After a Platinum Containing Regimen.

Canadian Cancer Trials Group·interventional·Posted Jan 13, 2014·Updated Aug 22, 2023

In Brief

A Phase 2 clinical trial evaluating Nab-Paclitaxel and Paclitaxel for Urothelial Cancer. Completed, enrolled 199 participants across 37 sites in 2 countries.

Detailed Summary

The purpose of this study is to compare the effects on urothelial cancer of nab-paclitaxel compared to paclitaxel to treat this disease. This research is being done because currently there is no effective treatment for urothelial cancer that has progressed after prior chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrothelial Cancer
CountriesAustralia, Canada
CollaboratorsAustralian and New Zealand Urogenital and Prostate Cancer Trials Group, Celgene

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 13, 2014
Enrollment StartMar 11, 2014
Primary CompletionMay 3, 2018
Study CompletionOct 28, 2020
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.5 years ago

Interventions

Nab-Paclitaxeldrug

Paclitaxeldrug